Published in the British Journal of Pharmacology in August 2021, this study examined the anticonvulsant effects of three acidic, precursor cannaninoids in a mouse model.
The results at lower doses were promising, however in some tests, larger doses of CBG-A actually increased seizure activity. This is consistent with several other cannabinoids, especially THC, that exhibit a biphasic dose response - a large dose can gice the opposite effect of a small dose. This is why it is so important for patients and consumers to START LOW (dose) and GO SLOW (increasing the dose). More is NOT always better with cannabinoids.
"The initial screen identified three phytocannabinoids with novel anticonvulsant properties: CBGA, cannabidivarinic acid (CBDVA) and cannabigerovarinic acid (CBGVA). CBGA was most potent and potentiated the anticonvulsant effects of clobazam against hyperthermia-induced and spontaneous seizures, and was anticonvulsant in the MES threshold test."
The abstract is here at the British Pharmacological Society's website.